DENAS, GENTIAN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.711
AS - Asia 1.036
EU - Europa 724
SA - Sud America 320
AF - Africa 231
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 15
Totale 6.056
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.611
SG - Singapore 330
CN - Cina 279
BR - Brasile 228
HK - Hong Kong 131
DE - Germania 119
IT - Italia 81
FI - Finlandia 76
SE - Svezia 74
VN - Vietnam 59
NL - Olanda 46
PL - Polonia 40
GB - Regno Unito 37
RU - Federazione Russa 31
CI - Costa d'Avorio 25
FR - Francia 25
AR - Argentina 19
BE - Belgio 18
IN - India 17
EC - Ecuador 15
JP - Giappone 15
AT - Austria 14
CA - Canada 14
IE - Irlanda 13
UA - Ucraina 13
CO - Colombia 12
IQ - Iraq 12
TR - Turchia 12
MX - Messico 11
CZ - Repubblica Ceca 10
ES - Italia 10
MD - Moldavia 10
MW - Malawi 10
BA - Bosnia-Erzegovina 9
CL - Cile 9
CY - Cipro 9
EG - Egitto 9
GR - Grecia 9
MA - Marocco 9
PH - Filippine 9
PY - Paraguay 9
TW - Taiwan 9
VE - Venezuela 9
ZA - Sudafrica 9
AZ - Azerbaigian 8
BG - Bulgaria 8
CM - Camerun 8
LB - Libano 8
UZ - Uzbekistan 8
YE - Yemen 8
AM - Armenia 7
BY - Bielorussia 7
CV - Capo Verde 7
DO - Repubblica Dominicana 7
GN - Guinea 7
GP - Guadalupe 7
ID - Indonesia 7
IL - Israele 7
JO - Giordania 7
KG - Kirghizistan 7
KZ - Kazakistan 7
ML - Mali 7
MY - Malesia 7
NP - Nepal 7
PE - Perù 7
PK - Pakistan 7
RO - Romania 7
SO - Somalia 7
TJ - Tagikistan 7
ZW - Zimbabwe 7
AE - Emirati Arabi Uniti 6
BS - Bahamas 6
CU - Cuba 6
DJ - Gibuti 6
DZ - Algeria 6
JM - Giamaica 6
MG - Madagascar 6
NC - Nuova Caledonia 6
PA - Panama 6
RS - Serbia 6
SN - Senegal 6
TN - Tunisia 6
UY - Uruguay 6
XK - ???statistics.table.value.countryCode.XK??? 6
AL - Albania 5
AO - Angola 5
BJ - Benin 5
BW - Botswana 5
EU - Europa 5
GA - Gabon 5
GH - Ghana 5
GM - Gambi 5
IS - Islanda 5
KE - Kenya 5
KH - Cambogia 5
LV - Lettonia 5
NG - Nigeria 5
SA - Arabia Saudita 5
SD - Sudan 5
SI - Slovenia 5
Totale 5.868
Salva come PNG Salva come JPEG
Città #
Fairfield 613
Ashburn 395
Woodbridge 319
Chandler 318
Ann Arbor 243
Houston 237
Cambridge 233
Singapore 221
Seattle 195
Wilmington 183
Hong Kong 125
Beijing 101
Santa Clara 75
Boardman 68
San Diego 50
Princeton 48
Munich 46
Medford 45
Des Moines 40
Helsinki 36
Bytom 32
Nanjing 29
Dong Ket 27
Abidjan 25
Frankfurt am Main 25
Los Angeles 23
Padova 21
New York 19
Roxbury 17
Redondo Beach 15
Nanchang 12
Shenyang 12
Buffalo 11
Dublin 11
Guangzhou 10
Turku 10
Brussels 9
Hefei 9
Baku 8
Falkenstein 8
Ho Chi Minh City 8
London 8
Nuremberg 8
Bamako 7
Belo Horizonte 7
Bishkek 7
Boston 7
Cairo 7
Chicago 7
Conakry 7
Dushanbe 7
Falls Church 7
Harare 7
Minsk 7
São Paulo 7
Tashkent 7
Tokyo 7
Vienna 7
Warsaw 7
Yerevan 7
Zhengzhou 7
Amman 6
Athens 6
Chisinau 6
Dakar 6
Dearborn 6
Goiânia 6
Hebei 6
Istanbul 6
Jinan 6
Johannesburg 6
Lilongwe 6
Limassol 6
Panama City 6
Praia 6
Redwood City 6
Antananarivo 5
Baghdad 5
Chennai 5
Djibouti 5
Douala 5
Gaborone 5
Guayaquil 5
Havana 5
Libreville 5
Lima 5
Luanda 5
Nassau 5
Noumea 5
Phnom Penh 5
Phoenix 5
Pristina 5
Santiago 5
Sofia 5
Stockholm 5
Accra 4
Addis Ababa 4
Almaty 4
Bangkok 4
Belgrade 4
Totale 4.279
Salva come PNG Salva come JPEG
Nome #
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naive Patients with Non-Valvular Atrial Fibrillation 220
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 183
Diagnosis and therapy of antiphospholipid syndrome 181
Laboratory testing for antiphospholipid syndrome 181
APS - Diagnostics and challenges for the future 172
Antiphospholipid syndrome and the heart: A case series and literature review 166
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 161
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. 160
Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns 156
An unusual acute coronary syndrome: undisclosed disease hidden under a confounding clinical presentation 154
Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation 154
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant 153
Dyspnoea in a young woman: the opposite of every truth is just as true 152
Lupus anticoagulant testing: Diluted Russell Viper Venom Time (dRVVT) 150
Interpretation of laboratory data and need for reference laboratories. 148
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 148
The Paradox of the Lupus Anticoagulant: History and Perspectives 148
A Bridging Protocol in High-Thrombotic Risk Mechanical Valve Bearers Undergoing Surgery or Invasive Procedures 143
Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study 143
One-Year Outcomes After Transapical Echocardiography-Guided Mitral Valve Repair 140
Correct laboratory approach to APS diagnosis and monitoring 138
The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients 138
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial 135
Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy 135
An Approach to Differential Diagnosis of Antiphospholipid Antibody Syndrome and Related Conditions 133
Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation 131
Laboratory Diagnostics of Antiphospholipid Syndrome 130
Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective 128
Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study 126
Secondary prevention in thrombotic antiphospholipid syndrome. 121
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs 120
Reference values for 3D echo parameters describing left ventricular mechanics obtained by vendor-independent software 118
Relationship of 3D left ventricular mass with systolic and diastolic function indices in hypertrophic cardiomyopathy 117
Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study 116
Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis 116
To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort 111
Normal left ventricular mechanics by two-dimensional speckle-tracking echocardiography. Reference values in healthy adults 111
Reference values of right ventricular longitudinal strain by speckle tracking echocardiography in 219 healthy volunteers 109
Impact of COVID-19 and COVID-19 vaccination on high-risk patients with Antiphospholipid Syndrome: a nationwide survey 107
Optimizing quality care for the oral vitamin K antagonists (VKAs) 105
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma 103
Investigational anticoagulants for hematological conditions: a new generation of therapies 101
The role of platelets in antiphospholipid syndrome 93
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. 89
Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study 72
Totale 6.116
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.516
article - articoli 20.516
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.032
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021355 0 0 0 30 13 36 23 40 73 24 47 69
2021/2022713 40 70 89 52 17 48 41 80 29 16 59 172
2022/2023557 116 67 15 74 84 63 2 40 53 4 33 6
2023/2024218 7 34 25 22 7 34 14 27 5 5 19 19
2024/20251.170 6 81 72 47 139 14 93 103 83 30 192 310
2025/20261.180 243 374 543 20 0 0 0 0 0 0 0 0
Totale 6.116